Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)

Key features and details

  • Rabbit polyclonal to Alpha-synuclein (phospho Y125)
  • Suitable for: ELISA
  • Reacts with: Recombinant fragment
  • Isotype: IgG

Overview

Properties

Applications

Fast track antibodies constitute a diverse group of products that have been released to accelerate your research, but are not yet fully characterized. They have all been affinity purified and show high titre values against the immunizing peptide (by ELISA). Fast track terms of use

Guaranteed

Tested applications are guaranteed to work and covered by our Abpromise guarantee.

Predicted

Predicted to work for this combination of applications and species but not guaranteed.

Incompatible

Does not work for this combination of applications and species.

Application Species
ELISA
Recombinant fragment
All applications
Mouse
Rat
Human
Application Abreviews Notes
ELISA
Use at an assay dependent concentration.
Notes
ELISA
Use at an assay dependent concentration.

Target

  • Function

    May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.

  • Tissue specificity

    Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

  • Involvement in disease

    Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
    Parkinson disease 1
    Parkinson disease 4
    Dementia Lewy body

  • Sequence similarities

    Belongs to the synuclein family.

  • Domain

    The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.

  • Post-translational
    modifications

    Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
    Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
    Ubiquitinated. The predominant conjugate is the diubiquitinated form.
    Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.

  • Cellular localization

    Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • Alpha synuclein antibody
    • Alpha-synuclein antibody
    • Alpha-synuclein, isoform NACP140 antibody
    • alphaSYN antibody
    • MGC105443 antibody
    • MGC110988 antibody
    • MGC127560 antibody
    • MGC64356 antibody
    • NACP antibody
    • Non A beta component of AD amyloid antibody
    • Non A4 component of amyloid antibody
    • Non A4 component of amyloid precursor antibody
    • Non-A beta component of AD amyloid antibody
    • Non-A-beta component of alzheimers disease amyloid , precursor of antibody
    • Non-A4 component of amyloid precursor antibody
    • Non-A4 component of amyloid, precursor of antibody
    • OTTHUMP00000218549 antibody
    • OTTHUMP00000218551 antibody
    • OTTHUMP00000218552 antibody
    • OTTHUMP00000218553 antibody
    • OTTHUMP00000218554 antibody
    • PARK 1 antibody
    • PARK 4 antibody
    • PARK1 antibody
    • PARK4 antibody
    • Parkinson disease (autosomal dominant, Lewy body) 4 antibody
    • Parkinson disease familial 1 antibody
    • SNCA antibody
    • Snca synuclein antibody
    • Snca synuclein, alpha (non A4 component of amyloid precursor) antibody
    • SYN antibody
    • Synuclein alpha antibody
    • Synuclein alpha 140 antibody
    • Synuclein, alpha (non A4 component of amyloid precursor) antibody
    • SYUA_HUMAN antibody
    see all

Images

This Fast-Track antibody is not yet fully characterised. These images represent inconclusive preliminary data.

  • ELISA - Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)
    ELISA - Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)
    ab10789 gave a positive result in ELISA against the immunising peptide (ab17030, blue line). It gave a negative result in ELISA against the non-modified equivalent peptide (ab17041, red line). This indicates that it is specific for the modified peptide. Not yet tested in other applications.

References (7)

Publishing research using ab10789? Please let us know so that we can cite the reference in this datasheet.

ab10789 has been referenced in 7 publications.

  • Krejciova Z  et al. Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human a-synuclein. Acta Neuropathol Commun 7:81 (2019). PubMed: 31109379
  • Vicente Miranda H  et al. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Sci Rep 7:13713 (2017). PubMed: 29057912
  • Kiely AP  et al. a-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 125:753-69 (2013). ICC/IF ; Human . PubMed: 23404372
  • Schiess MC  et al. CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes. BMC Neurosci 11:151 (2010). ICC/IF ; Human . PubMed: 21114836
  • Dinh K  et al. Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Cytokine 45:179-83 (2009). ICC/IF ; Human . PubMed: 19157893
  • Chen L  et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest : (2009). WB ; Drosophila melanogaster . PubMed: 19855133
  • Bick RJ  et al. Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Brain Res 1217:203-12 (2008). ICC/IF ; Human . PubMed: 18501880

Images

  • ELISA - Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)
    ELISA - Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)
    ab10789 gave a positive result in ELISA against the immunising peptide (ab17030, blue line). It gave a negative result in ELISA against the non-modified equivalent peptide (ab17041, red line). This indicates that it is specific for the modified peptide. Not yet tested in other applications.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Alpha-synuclein (phospho Y125) antibody (ab10789)

Sign up